Sept. 5, 2025 — Idorsia Ltd has announced a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes and worsening outcomes. The initiative, led by Dr. Vivek Bhalla, Stanford University School of Medicine, and Dr. Sreekanth Vemulapalli, Duke University School of Medicine, is expected to generate real-world evidence, standardize clinical decision-making and deliver scalable tools that leverage AI technology to help identify patients with difficult-to-control hypertension who may benefit from innovative therapies that use new pathways, including Idorsia's once-daily Tryvio (aprocitentan).
Sreekanth Vemulapalli, MD, Associate Professor of Medicine, Duke Heart Center, said, "With novel therapies emerging to improve hypertension control, we are thrilled to work with our esteemed colleagues at Stanford and other hypertension centers to standardize the evaluation, management and access to innovative therapies for our patients with difficult-to-control hypertension. We'll be collaborating with companies to develop high-touch AI tools aimed at supporting the care of our patients to meet people where they are. This is a cross-institutional collaboration which we hope to expand to improve the outcomes of our patients."
Hypertension remains a major global health issue, affecting an estimated 50% of adults in the U.S. Patients whose blood pressure remains above target despite the use of appropriate therapy face significantly higher risks of cardiovascular events and are nearly twice as likely to experience premature mortality compared to those with controlled blood pressure.
"The IMPACT-HTN program challenges the boundaries of the standard care model for hypertension treatment by building a platform to fundamentally shift how we approach difficult-to-control hypertension, said Vivek Bhalla, MD, Associate Professor of Medicine/Nephrology, founding director of the Stanford Hypertension Center. "I'm proud to collaborate with Idorsia and Dr. Vemulapalli as well as Dr. Kenneth Mahaffey, the founding director of the Stanford Center for Clinical Research, for this initiative. By developing and publishing best practices, analyzing real-world data, and harnessing emerging technologies, we're working to deliver impactful solutions that can transform hypertension care and improve lives."
The multi-phased IMPACT-HTN program is expected to deliver actionable tools, data, and insights to improve care including:
- A digital care algorithm to standardize how difficult-to-control hypertension is assessed and managed. Through interactive tools such as patient-facing algorithms, AI chatbots, and a program portal, this initiative aims to transform protocols to improve patient care.
- A personalized hypertension risk score that will build on existing risk scores for prevention to better identify difficult-to-control hypertension patients at risk for negative cardiovascular outcomes so appropriate treatment protocols can be implemented sooner.
- A prospective early patient experience initiative that will enroll patients from hypertension specialty centers to better understand the treatment obstacles for patients with difficult-to-control hypertension and how newer treatments, like Idorsia's Tryvio, are impacting the treatment paradigm.
Srishti Gupta, MD, CEO of Idorsia, commented, "We are proud to have pioneered the first treatment tackling a new pathway in hypertension in over three decades and as a leader in this area, we understand that our commitment to improving patient outcomes goes beyond the medicine. We are proud to collaborate with two of the world's leading research institutions on this exciting new program and believe IMPACT-HTN will help reimagine the pathways of care for hypertension patients who need additional options."
Tryvio, a dual endothelin receptor antagonist (ERA), is now available to prescribe. It is indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Tryvio is now included in the American College of Cardiology's (ACC) and the American Heart Association's (AHA) new comprehensive clinical practice guidelines for the management of high blood pressure, but many patients remain undiagnosed and undertreated.
For more information, go to www.indorsia.com.
September 09, 2025 
